Eliquis (Apixaban) Regulatory Postmarketing Surveillance In Real World Practice (rPMS) For Venous Thromboembolism (VTE) Treatment And Prevention Of Recurrent VTE
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.
- 10 May 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Sep 2017.